Avita Medical (RCEL) Projected to Post Quarterly Earnings on Thursday

Key Points

• Avita Medical is scheduled to release its Q2 2025 earnings report on August 7th, with analysts expecting an earnings loss of ($0.26) per share and revenue of $34.27 million.
• In its previous earnings report, the company reported a loss of ($0.53) per share, missing the consensus estimate, and had a significant negative net margin of 79.61%.
• Analysts maintain an optimistic outlook, with D. Boral Capital setting a target price of $19.00, despite current trading around $5.36.

Avita Medical (NASDAQ:RCEL - Get Free Report) is expected to post its Q2 2025 quarterly earnings results after the market closes on Thursday, August 7th. Analysts expect Avita Medical to post earnings of ($0.26) per share and revenue of $34.27 million for the quarter. Avita Medical has set its FY 2025 guidance at EPS.

Avita Medical (NASDAQ:RCEL - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.14). The firm had revenue of $18.51 million during the quarter, compared to analyst estimates of $33.15 million. Avita Medical had a negative return on equity of 632.62% and a negative net margin of 79.61%. On average, analysts expect Avita Medical to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Avita Medical Price Performance

Shares of NASDAQ:RCEL traded down $0.14 during trading on Friday, reaching $5.16. The stock had a trading volume of 321,032 shares, compared to its average volume of 255,325. The company has a debt-to-equity ratio of 9.39, a quick ratio of 1.72 and a current ratio of 2.09. The business has a fifty day moving average price of $5.59 and a 200-day moving average price of $7.67. The stock has a market cap of $136.38 million, a PE ratio of -2.36 and a beta of 1.63. Avita Medical has a 1-year low of $4.71 and a 1-year high of $14.16.

Analyst Upgrades and Downgrades

Separately, D. Boral Capital reaffirmed a "buy" rating and issued a $19.00 price target on shares of Avita Medical in a research note on Friday, June 6th.

Hedge Funds Weigh In On Avita Medical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RCEL. AQR Capital Management LLC acquired a new position in Avita Medical during the first quarter worth $799,000. Jacobs Levy Equity Management Inc. acquired a new position in Avita Medical during the first quarter worth $374,000. Jane Street Group LLC boosted its stake in Avita Medical by 20.4% during the first quarter. Jane Street Group LLC now owns 63,744 shares of the company's stock worth $519,000 after buying an additional 10,789 shares during the last quarter. Finally, Strs Ohio acquired a new position in Avita Medical during the first quarter worth $116,000. Institutional investors and hedge funds own 27.66% of the company's stock.

About Avita Medical

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.